Pernix Therapeutics (PTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pernix Therapeutics Reports Second Quarter 2015 Financial Results
August 6, 2015 6:50 AM EDTRevenues Increase Over 150% Year-Over-Year
Company Provides Updated Financial Guidance
MORRISTOWN, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) ("Pernix" or "the Company"), a specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2015. Second Quarter and Recent Business Highlights:
Treximet sales and volumes increased significantly, arresting a multi-year decline and demonstrating a clear trend reversal:o     Total prescriptions increased 10% since sampling was initiated at the end of March
o     New prescriptions increased by 15% over the same time period
o     ... More
Pernix Therapeutics Reports Second Quarter 2015 Financial Results
August 6, 2015 6:50 AM EDTRevenues Increase Over 150% Year-Over-Year
Company Provides Updated Financial Guidance
MORRISTOWN, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) ("Pernix" or "the Company"), a specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2015. Second Quarter and Recent Business Highlights:
Treximet sales and volumes increased significantly, arresting a multi-year decline and demonstrating a clear trend reversal:o     Total prescriptions increased 10% since sampling was initiated at the end of March
o     New prescriptions increased by 15% over the same time period
o     ... More
